Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders
Joost P.H. Drenth, Stephen G. Waxman
Joost P.H. Drenth, Stephen G. Waxman
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):3603-3609. https://doi.org/10.1172/JCI33297.
View: Text | PDF
Science in Medicine Article has an altmetric score of 67

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

  • Text
  • PDF
Abstract

The voltage-gated sodium-channel type IX α subunit, known as Nav1.7 and encoded by the gene SCN9A, is located in peripheral neurons and plays an important role in action potential production in these cells. Recent genetic studies have identified Nav1.7 dysfunction in three different human pain disorders. Gain-of-function missense mutations in Nav1.7 have been shown to cause primary erythermalgia and paroxysmal extreme pain disorder, while nonsense mutations in Nav1.7 result in loss of Nav1.7 function and a condition known as channelopathy-associated insensitivity to pain, a rare disorder in which affected individuals are unable to feel physical pain. This review highlights these recent developments and discusses the critical role of Nav1.7 in pain sensation in humans.

Authors

Joost P.H. Drenth , Stephen G. Waxman

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 Total
Citations: 4 8 12 5 9 11 12 8 9 8 3 6 8 7 8 13 9 4 144
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2017 (9)

Title and authors Publication Year
Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean, CJ Woolf
Nature Reviews Drug Discovery 2017
Network topology of NaV1.7 mutations in sodium channel-related painful disorders
D Kapetis, J Sassone, Y Yang, B Galbardi, MN Xenakis, RL Westra, R Szklarczyk, P Lindsey, CG Faber, M Gerrits, IS Merkies, SD Dib-Hajj, M Mantegazza, SG Waxman, G Lauria
BMC Systems Biology 2017
Sodium channels in pain disorders: pathophysiology and prospects for treatment
SD Dib-Hajj, P Geha, SG Waxman
PAIN 2017
Sodium channels and pain: from toxins to therapies: Sodium channels and pain
FC Cardoso, RJ Lewis
British Journal of Pharmacology 2017
Gain-of-function mutation of a voltage-gated sodium channel Na V 1.7 associated with peripheral pain and impaired limb development
BS Tanaka, PT Nguyen, EY Zhou, Y Yang, V Yarov-Yarovoy, SD Dib-Hajj, SG Waxman
The Journal of biological chemistry 2017
Nonlinear effects of hyperpolarizing shifts in activation of mutant Na v 1.7 channels on resting membrane potential
M Estacion, SG Waxman
Journal of neurophysiology 2017
Between fire and ice: refractory hypothermia and warmth-induced pain in inherited erythromelalgia
SW Tham, L Li, P Effraim, S Waxman
BMJ case reports 2017
Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Na v 1.7 mutation I234T: Carbamazepine-responsive Na v 1.7-I234T
Y Yang, T Adi, PR Effraim, L Chen, SD Dib-Hajj, SG Waxman
British Journal of Pharmacology 2017
Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors
BA Sparling, S Yi, J Able, H Bregman, EF DiMauro, RS Foti, H Gao, A Guzman-Perez, H Huang, M Jarosh, T Kornecook, J Ligutti, BC Milgram, BD Moyer, B Youngblood, VL Yu, MM Weiss
MedChemComm 2017

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 6 news outlets
Blogged by 1
Posted by 8 X users
Referenced in 25 patents
Referenced in 2 Wikipedia pages
267 readers on Mendeley
2 readers on CiteULike
See more details